Advanced search    

Search: authors:"G. Bevilacqua"

12 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Hard photons in hadroproduction of top quarks with realistic final states

. Pozzorini, NLO QCD corrections to WWbb production at hadron colliders, Phys. Rev. Lett. 106 (2011) 052001 [arXiv:1012.3975] [INSPIRE].ADSCrossRefGoogle Scholar [23] G. Bevilacqua, M. Czakon, A. van Hameren ... top-antitop production with leptonic decays in association with a Higgs boson at the LHC, JHEP 11 (2015) 209 [arXiv:1506.07448] [INSPIRE].ADSCrossRefGoogle Scholar [29] G. Bevilacqua, H.B. Hartanto, M

Top quark mass studies with $$ t\overline{t}j $$ at the LHC

. Butterworth et al., PDF4LHC recommendations for LHC Run II, J. Phys. G 43 (2016) [33] G. Bevilacqua et al., HELAC-NLO, Comput. Phys. Commun. 184 (2013) 986 [34] M. Czakon, C.G. Papadopoulos and M. Worek ... , Polarizing the Dipoles, JHEP 08 (2009) 085 [35] G. Bevilacqua, M. Czakon, M. Kubocz and M. Worek, Complete Nagy-Soper subtraction for next-to-leading order calculations in QCD, JHEP 10 (2013) 204 [arXiv

Off-shell top quarks with one jet at the LHC: a comprehensive analysis at NLO QCD

and B.R. Webber, Matching NLO QCD computations and parton shower [40] G. Bevilacqua, H.B. Hartanto, M. Kraus and M. Worek, Top Quark Pair Production in [41] A. Denner, S. Dittmaier, S. Kallweit and S ... . Pozzorini, NLO QCD corrections to WWbb [42] G. Bevilacqua, M. Czakon, A. van Hameren, C.G. Papadopoulos and M. Worek, Complete [43] A. Denner, S. Dittmaier, S. Kallweit and S. Pozzorini, NLO QCD corrections

On the ratio of \( t\overline{t} b\overline{b} \) and \( t\overline{t} jj \) cross sections at the CERN Large Hadron Collider

G. Bevilacqua 1 M. Worek 0 0 Institute for Theoretical Particle Physics and Cosmology, RWTH Aachen University , Otto-Blumenthal Str., D-52056 Aachen, Germany 1 INFN, Laboratori Nazionali di

Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling

Background: Although most BRCA sequence variants are clearly deleterious and unequivocally pathogenetic, several are still classified as variants of unknown significance. Patients and methods: We followed families undergoing oncogenetic counseling from risk identification to risk definition by genetic testing and risk management. Results: We identified two germline mutations in...

Small cell lung cancer

Small cell lung cancer accounts for 13–15% of all lung cancer worldwide. There has been a decrease in the number of cases, with no clear explanation, except probably to changing in smoking habits in the last two decades. In the early eighties, it became clear that SCLC was an extremely sensitive tumor as to radiation as to chemotheraputic agents. With cisplatinum etoposide...

Germline mutations of BRCA1-associated RING domain (BARD1) gene in breast and/or ovarian families negative for BRCA1 and 2 alterations

C Ghimenti*, E Sensi*, D Iandolo*, G Cipollini*, S Ricci, PF Conte, G Bevilacqua* and MA Caligo* Department of Oncology, *Division of Pathology and Division of Medical Oncology, University of Pisa

P53 mutations in breast and ovarian carcinomas from BRCA1 and 2 mutation carriers and noncarriers

C Ghimenti*, E Sensi*, D Iandolo*, G Cipollini*, S Ricci, PF Conte, G Bevilacqua* and MA Caligo* Department of Oncology, *Division of Pathology and Division of Medical Oncology, University of Pisa

Genetic alterations in hereditary breast cancer

Genetic linkage studies have led to the identification of highly penetrant genes as the possible cause of inherited cancer risk in many cancer-prone families. Most women with a family history of breast/ovarian cancer have tumors characterized by alterations in particular genes, mainly BRCA1 and BRCA2, but also CHK2, ATM, STK11 and others. This paper examines the BRCA1 and BRCA2...

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program

G. Bevilacqua Department of Oncology, University of Pisa and Pisa University Hospital , Pisa, Italy 11 D. Tiniakos Laboratory of Histology and Embryology, Medical School University of Athens , Athens

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program

Nijmegen Medical Centre , Nijmegen, The Netherlands 11 A. Ensari Department of Pathology, Ankara University Medical School , Ankara, Turkey 12 G. Bevilacqua Department of Oncology, University of Pisa and